CASTLE BIOSCIENCES INC
About CASTLE BIOSCIENCES INC
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $344.2M
- Net income
- -$24.2M
- Total assets
- $578.6M
- Market cap
- $637.2M
- Gross margin
- 79.4%
- Operating margin
- -12.4%
- Net margin
- -7.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $344.2M
- Cost of revenue
- $71.0M
- Gross profit
- $273.2M
- Operating expenses
- $316.0M
- Operating income
- -$42.8M
- Income tax
- -$5.4M
- Net income
- -$24.2M
- EPS (basic)
- $-0.83
- EPS (diluted)
- $-0.83
Balance sheet
- Total assets
- $578.6M
- Current assets
- $361.1M
- Total liabilities
- $107.7M
- Current liabilities
- $68.7M
- Shareholders’ equity
- $470.9M
Cash flow
- Operating cash flow
- $64.3M
- Investing cash flow
- -$60.4M
- Financing cash flow
- -$7.0M
- Net cash flow
- -$3.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $637.2M
- EPS (diluted)
- $-0.83
- Shares outstanding
- 31.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $24.2M in FY2025.
- Revenue grew 449% from FY2020 to FY2025.
- Gross margin of 79.4%, net margin -7.0%.
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CASTLE BIOSCIENCES INC.
Write a review
News about CASTLE BIOSCIENCES INC
News & sentiment via Polygon.io
